Unmasking Early Cardiac Fibrosis in Sarcoidosis: The Role of Plasma Aldosterone and Cardiac MRI

<b>Background/Objectives:</b> Cardiac sarcoidosis (CS) is a challenging diagnosis due to its subclinical progression and the limitations of existing screening tools. Cardiac magnetic resonance (CMR) and PET/CT imaging have improved diagnosis and detection. Aldosterone, a hormone with known profibrotic effects, may offer additional diagnostic value. We therefore aimed to determine whether plasma aldosterone level is associated with myocardial fibrosis, independent of active inflammation, in CS. <b>Methods:</b> This observational study included 541 patients with biopsy-proven sarcoidosis and preserved left ventricular ejection fraction (LVEF ≥ 50%). All underwent CMR with extracellular volume (ECV) mapping and 18F-FDG PET/CT to assess myocardial fibrosis and inflammation, respectively. Plasma aldosterone levels were also measured. <b>Results:</b> Plasma aldosterone levels were significantly higher in patients with cardiac sarcoidosis (172 [IQR 106-235] pg/mL) compared to those without cardiac involvement (143 [100-205] pg/mL, <i>p</i> = 0.02). Aldosterone was independently associated with the presence of late gadolinium enhancement (LGE) on CMR (OR 1.002 per 1 pg/mL increase; 95% CI 1.001-1.004, <i>p</i> = 0.04) and with higher ECV values (β = 0.008 per 1 pg/mL, <i>p</i> = 0.001). Regression analysis showed that aldosterone is associated with ECV (b-0.009, CI: 0.002-0.016, <i>p</i> = 0.009) and there was no interaction according to LGE status indicating a relationship with diffuse myocardial fibrosis even in the absence of visible scarring. No association was observed with T1-, T2-, or PET/CT-defined inflammation. <b>Conclusions:</b> Plasma aldosterone is a robust marker of myocardial fibrosis in sarcoidosis, particularly in early or subclinical stages. Its correlation with ECV-but not with inflammatory imaging markers-suggests its link with myocardial diffuse fibrotic remodeling before, and independently of, overt scarring or inflammation.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-01-14
DOI
https://doi.org/10.3390/jcm15020650
Primary Topic
Sarcoidosis and Beryllium Toxicity Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Unmasking Early Cardiac Fibrosis in Sarcoidosis: The Role of Plasma Aldosterone and Cardiac MRI

Evaggelos Markozanes, Elias Giallafos, Grigoris Stratakos, Varvara Pantoleon et al.
Journal of Clinical Medicine
Sarcoidosis and Beryllium Toxicity Research
article

Unmasking Early Cardiac Fibrosis in Sarcoidosis: The Role of Plasma Aldosterone and Cardiac MRI

Evaggelos Markozanes, Elias Giallafos, Grigoris Stratakos, Varvara Pantoleon, Lykourgos Kolilekas, Γεώργιος Μαρίνος, Niki Lama, GERASIMOS SIASOS, S.A. Papiris, K Zisimos, Spiros Katsanos, ILIAS IOANNIS, Gesthimani Seitaridi, Evangelos Oikonomou, Ourania Katsarou, Konstantinos Tsioufis, Effrosyni D. Manali, Nikos Kelekis
article en

Abstract

<b>Background/Objectives:</b> Cardiac sarcoidosis (CS) is a challenging diagnosis due to its subclinical progression and the limitations of existing screening tools. Cardiac magnetic resonance (CMR) and PET/CT imaging have improved diagnosis and detection. Aldosterone, a hormone with known profibrotic effects, may offer additional diagnostic value. We therefore aimed to determine whether plasma aldosterone level is associated with myocardial fibrosis, independent of active inflammation, in CS. <b>Methods:</b> This observational study included 541 patients with biopsy-proven sarcoidosis and preserved left ventricular ejection fraction (LVEF ≥ 50%). All underwent CMR with extracellular volume (ECV) mapping and 18F-FDG PET/CT to assess myocardial fibrosis and inflammation, respectively. Plasma aldosterone levels were also measured. <b>Results:</b> Plasma aldosterone levels were significantly higher in patients with cardiac sarcoidosis (172 [IQR 106-235] pg/mL) compared to those without cardiac involvement (143 [100-205] pg/mL, <i>p</i> = 0.02). Aldosterone was independently associated with the presence of late gadolinium enhancement (LGE) on CMR (OR 1.002 per 1 pg/mL increase; 95% CI 1.001-1.004, <i>p</i> = 0.04) and with higher ECV values (β = 0.008 per 1 pg/mL, <i>p</i> = 0.001). Regression analysis showed that aldosterone is associated with ECV (b-0.009, CI: 0.002-0.016, <i>p</i> = 0.009) and there was no interaction according to LGE status indicating a relationship with diffuse myocardial fibrosis even in the absence of visible scarring. No association was observed with T1-, T2-, or PET/CT-defined inflammation. <b>Conclusions:</b> Plasma aldosterone is a robust marker of myocardial fibrosis in sarcoidosis, particularly in early or subclinical stages. Its correlation with ECV-but not with inflammatory imaging markers-suggests its link with myocardial diffuse fibrotic remodeling before, and independently of, overt scarring or inflammation.

Journal of Clinical MedicineVol. 15(2)
National and Kapodistrian University of Athens (GR), Eginition Hospital (GR), Hippocration General Hospital (GR), Sotiria General Hospital (GR)
Good health and well-being
Openalex Percentile: Top 90%
Sarcoidosis and Beryllium Toxicity Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.